NCT04854005View on ClinicalTrials.gov

Use of Sentinel Lymph Node Biopsy in Patients With Early-Stage, Palpable Node-Positive HR+/HER2- Breast Cancer Having Upfront Surgery and Adjuvant Radiation

Active, not recruitingOBSERVATIONAL
Enrollment

78

Participants

Timeline

Start Date

April 20, 2021

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Breast Cancer
Interventions
PROCEDURE

Breast surgery

Patients will undergo SLNB with single or dual-tracer lymphatic with technetium-99m sulfur colloid either lymphazurin or methylene blue dye, per institution standard, in accordance with routine clinical practice.

Trial Locations (10)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester (Consent Only), Harrison

11553

Memorial Sloan Kettering Nassau (Consent Only), Uniondale

11725

Memorial Sloan Kettering Suffolk - Commack (Consent Only), Commack

18103

Lehigh Valley Health Network (Dara Collection Only), Allentown

48109

University of Michigan (Data Collection Only), Ann Arbor

06102

Hartford Healthcare Cancer Alliance (Data collection only), Hartford

07920

Memorial Sloan Kettering Basking Ridge (Consent Only), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown

07645

Memorial Sloan Kettering Bergen (Consent Only), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER